General Biotechnology

Biopharma’s next growth cycle won’t be won in the lab—it’ll be won in the tender room.
If you’re a commercial vendor selling into EU healthcare systems, you already know the pattern: as patents approach loss of exclusivity, payers tighten scrutiny, f…

Drug patent expiry dates aren’t just legal milestones—they’re commercial calendars. And most teams treat them like a compliance checkbox instead of a revenue engine.
Here’s the agitation: if you’re waiting until a patent is “about to expire” to build y…

The smarter monopoly isn’t a patent. It’s orphan exclusivity.
If you want to understand why drug prices stay sticky—even after patents expire—look past the headline-grabbing “patent cliff” and into a quieter mechanism: orphan drug exclusivity. It’s d…

Sell Before the Cliff: A Business Development Playbook for Sterile Manufacturing Suppliers Targeting Biologic LOE
Biologics don’t just “end”—they cliff. And when loss of exclusivity (LOE) hits, the market doesn’t politely wait for your pipeline to catc…

Generic competition isn’t just a legal event—it’s a business strategy.
For years, the industry narrative has been simple: once a patent expires, generics arrive, prices fall, and the market resets. But the real story—especially in branded pharmaceuti…

Patients don’t ask “What’s the patent status?”—they ask, “Will I be able to get my medicine tomorrow?”
That’s the real subtext behind the growing wave of online questions about drug switching. And it’s why the conversation around patents, exclusivity, …

Patent cliffs don’t just “happen.” They’re engineered—by timing, leverage, and payer behavior.
In pharma, the phrase patent cliff is often treated like weather: inevitable, disruptive, and largely outside your control. But the most effective companie…

Your drug’s “patent life” isn’t one number in the GCC. It’s a moving target.
If you’re launching (or defending) a branded medicine in the Gulf Cooperation Council, the biggest misconception is simple: patent term is the same everywhere.
In reality, t…

Biopharma teams don’t lose deals because they lack ambition. They lose because timing is misaligned.
In licensing, partnering, and BD strategy, the “pitch” is rarely just a pitch. It’s a calendar—built on patent life, regulatory milestones, and the ung…

OpenAI’s “GPT for life sciences” is getting the headlines—but the real question for drug developers isn’t what it can do in a demo. It’s what it changes in the messy, expensive, failure-prone reality of drug development.
That’s the subtext behind the l…